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Implications for Perioperative Care 
As defined by the Center for Disease Control (CDC, 2018), Creutzfeldt-Jakob Disease 
(CJD) is a rapidly progressive, rare, transmissible, and fatal illness. Miscoiling of  healthy 
proteins caused by an abnormal isoform of  cellular glycoprotein resulting in protein  
folding has been found to be the molecular mechanism during the pathological process  
of  this malady (Figure 1), (Castle, Gill, 2017).  
The current problem is that few recommendations are available for organizations to 
consider how to manage potential CJD patient cases, and institutions are left to compile 
and develop their own guidelines and/or protocols for clinical practice. The standards  
of  care for this rare disease in healthcare are evolving quickly and are often forged from 
experiences (Thomas et. al. , 2013).  
Outcome 
Approach 
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For a patient, the symptoms of  CJD are demonstrated by increasing memory  
impairment that progresses to dementia and the disease is always fatal usually within  
one year of  onset of  illness (Figure 2). 
 
The process started in November, 2016 to create prevention strategies and a policy for the 
interprofessional stakeholders in a large tertiary care organization. Pathway development 
was a multilayered shared process requiring extensive exploration and review of  current 
evidence to achieve consensus amongst stakeholders. The sequential efforts included 
practice gap identification, decision making, and role clarification on how to standardize 
care for the potential CJD population.  
This topic magnified the institutional vulnerability and safety risks inherent to a disease that 
is high risk, low volume, and with limited availability of  guidelines. The outcome of  the 
process was an institutional policy describing the identification and management of  patients 
with concerns for CJD. This policy extends to, but is not limited to, the perioperative area, 
interventional radiology, and the patient bedside. The provider is enabled with an 
interprofessional team to safely deliver evidence-based care for a patient whose neurological 
diagnosis is unclear. This work has introduced and discussed an approach that is replicable 
in other organizations that may consider developing a pathway and policy, in anticipation  
and preparation for managing patients who may undergo the undirected brain biopsy. 
 
The estimated occurrence of  CJD worldwide and in the United States has been reported to 
affect approximately 1:1,000,000 people per year (CDC, 2018). The prevalence of  CJD can 
be anticipated to increase (Figure 3). The signs and symptoms of  the disease are deceptive 
and brain biopsy is used to support conclusive diagnosis. Increased awareness and 
proactivity, as indicated also by AORN,  will safeguard the OR environment, staff, patients 
and families, and the institution against this insidious disease (Anderson, 2018). Our 
recommendation is that every institution considers a policy and a pathway that provides 
guidance to the interprofessional team clarifying expectations, roles and responsibilities, and 
offering tools for managing patients with concerns for CJD.  Together, this work serves to 
prepare for a one in one million opportunity. 
Figure 3. Creutzfeldt-Jakob Disease Deaths and Age-Adjusted Death Rate, United States, 1979-2016  
(Centers for Disease Control and Prevention, 2018).   
  
 
Jeffrey E. Florman, MD, Physician, MMP Neuro & Spine-Neurosurgery 
Eira Kristiina Hyrkas, PhD, LicNSc, MNSc, RN, Director, Center for Nursing Research and Quality Outcomes, MMC  
 
 
Literature Review  
and  
Expert Consultations 
• The CDC and World Health Organization were consulted. They provided general guidelines and 
recommendations for the management of  the patient with CJD in the hospital organization. 
• A comprehensive literature search and review was completed. The content of  the current literature 
focused primarily on the microbiological aspect of  the disease, the transmission, the incidence, and the 
fatality of  CJD.  
• Fifteen round table discussions were conducted with experts from Perioperative Leadership, 
Neurology, Neurosurgery, Anesthesia, Pathology, Infection Prevention, Safety Management and Risk 
Management. These meetings focused on risk screening and symptom identification.  
Patient  
Identification 
• Agreed screening criteria: any patient with symptoms of  rapidly progressive dementia, ataxia, 
encephalopathy or neuropsychological symptoms without clear etiology will be identified as a risk for 
CJD. 
• Testing: at risk patients will undergo further testing and have a lumbar puncture screening for 14-3-3 
protein. If  positive, a non-directed brain biopsy will follow. If  negative, additional testing needs to be 
considered. 
• Operating Room: any patient with rapidly progressing neurological symptoms and undergoing    
non-directed brain biopsy will be treated under the high infectivity prion protocol. 
 
 
Multidirectional 
Coordination 
 
 
 
• Roles, responsibilities, and patient flow coordination: the Surgeon in collaboration with the 
Neurologist and provider caring for the patient, who have identified a patient at risk for prion disease, 
will determine and coordinate the most appropriate location for testing.  
• Once the proceduralist and the appropriate location have been determined, Infection Prevention (IP) 
is notified of  the proposed surgery/procedure. IP then deploys communication to affected 
departments in preparation for procedure. 
• Timeline: no less than 24 hours is given to allow for involved departments and teams to coordinate 
preparations to conduct procedure. 
 
 
 
 
 
Communication  
Tools 
 
• Policy: is readily and electronically available for all departments and stakeholders. 
• Huddle: pre-procedure huddle in the OR is crucial and called upon by the sponsor of  the policy. This 
huddle includes: Neurosurgeon, Anesthesiologist, Circulating RN, Surgical Technologist, and support 
staff. The policy is reviewed and roles and responsibilities are clearly assigned. 
• Additional communication tool: red Protocol Stop Signs are placed on all OR entrances and exits 
where the procedure will be performed. 
Interprofessional 
Debriefings 
• Debriefing: is organized by the policy sponsor after the procedure. This is designed as a structured 
process and the goal is to analyze the implementation of  the procedure whilst adhering to the policy.  
The focused discussion provides the interprofessional team an opportunity to enhance performance, 
optimize future procedures, identify communication breakdowns, and also highlight implementation 
success. 
• Documentation: content of  the discussion is electronically recorded and available for the leadership 
team of  the organization.  
This poster displays a quality 
improvement project and synthetizes the  
process and experiences of  how one 
organization transformed and optimized 
CJD prevention strategies. A pathway 
was developed that enhances patient 
identification, promotes multidirectional 
coordination, utilizes communication 
tools, and supports interprofessional 
debriefings, resulting in harmonized CJD 
patient care.  
 
Figure 1. Schematic representation of  cellular prion protein 
(Legname, 2017). 
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The potential presence of  CJD in the perioperative patient requires interprofessional 
care and team collaboration because the signs and symptoms of  this disease can be 
misleading. This includes not just perioperative staff, but also experts representing 
Neurology, Neurosurgery, Anesthesia, Pathology, Infection Prevention, and Safety 
Management, amongst others. Inpatient care teams, the patient, and families are also 
essential partners for collaboration.  
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